CRDF-004 Trial
1st Line RAS-mutated mCRC

Initial Data Release

DECEMBER 10, 2024

Forward-looking statements

CERTAIN STATEMENTS IN THIS PRESENTATION ARE FORWARD-LOOKING within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are based on our current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; early results from clinical trials may not be indicative of final results; our need for additional financing; risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and we do not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Mark Erlander, PhD

Chief Executive Officer

AGENDA

1. 1st line RAS-mut mCRC trial data (CRDF-004)
2. Commercial opportunity in 1st line mCRC
3. The broader onvansertib opportunity

Onvansertib specifically targets PLK1, a well-established cancer target

Onvansertib

First oral, well-tolerated PLK1-selective inhibitor

PROPERTIES

- Small molecule
- Oral dosing
- 24-hour half-life



SPECIFICITY

Exquisitely specific for PLK1

ENZYME	IC_{50} (µM)
PLK1	0.002
PLK2	>10
PLK3	>10
CK2	0.4
FLT3	0.4
CDK1/CycB	>10
42 other kinases and >140 in the Millipore panel	>10

AGENDA

1. **1st line RAS-mut mCRC trial data (CRDF-004)**

Fairooz Kabbinavar, MD, FACP

Chief Medical Officer

Trial design of CRDF-004: first-line RAS-mutated mCRC Phase 2 trial

ENROLLMENT CRITERIA

First-line mCRC

KRAS+/NRAS+

Unresectable

No prior bev

R
N=90



6 RANDOMIZATION ARMS

SoC alone	1. FOLFIRI/bev 2. FOLFOX/bev
Onv 20mg +	3. FOLFIRI/bev 4. FOLFOX/bev
Onv 30mg +	5. FOLFIRI/bev 6. FOLFOX/bev

ENDPOINTS *

Primary: ORR

Secondary: DoR and PFS

* Assessed by blinded independent central review (BICR)



Patients' tumors are scanned every 8 weeks

Trial design of CRDF-004: first-line RAS-mutated mCRC Phase 2 trial

ENROLLMENT CRITERIA

First-line mCRC

KRAS+/NRAS+

Unresectable

No prior bev

R
N=90



6 RANDOMIZATION ARMS

SoC alone	1. FOLFIRI/bev 2. FOLFOX/bev
Onv 20mg +	3. FOLFIRI/bev 4. FOLFOX/bev
Onv 30mg +	5. FOLFIRI/bev 6. FOLFOX/bev

ENDPOINTS *

Primary: ORR

Secondary: DoR and PFS

* Assessed by blinded independent central review (BICR)

OBJECTIVES OF THE TRIAL

1. Demonstrate onvansertib's efficacy in first-line RAS-mut mCRC
2. Evaluate two doses of onvansertib per FDA's Project Optimus
3. Demonstrate the safety and tolerability of onvansertib when combined with FOLFIRI/bev and FOLFOX/bev

Patient maturity across arms are balanced in the current data set



6 RANDOMIZATION ARMS

NUMBER OF EVALUABLE* PATIENTS TIME ON TRIAL

		2 mos	4 mos	6+mos	Total patients
SoC alone	1. FOLFIRI/bev 2. FOLFOX/bev	3	2	4	9
Onv 20mg +	3. FOLFIRI/bev 4. FOLFOX/bev	4	4	2	10
Onv 30mg +	5. FOLFIRI/bev 6. FOLFOX/bev	3	5	3	11
	Total patients	10	11	9	30

* Evaluable patients defined as those with at least their first post-baseline scan (2 months after beginning treatment). mos: months

ORR for the experimental arms is higher than for the control arms

Best Radiographic Response OVERALL* – as of November 26, 2024



* Radiographic response determined per RECIST 1.1 by blinded independent central review. Waterfall plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.

ORR for control and experimental arms is similar for FOLFIRI and FOLFOX

Best Radiographic Response BY CHEMO BACKBONE* – as of November 26, 2024



* Radiographic response determined per RECIST 1.1 by blinded independent central review. Waterfall plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.

Dose response: Higher onvansertib dose shows increased ORR with deeper responses

Best Radiographic Response BY ONVANSERTIB DOSE* – as of November 26, 2024

* Radiographic response determined per RECIST 1.1 by blinded independent central review. Waterfall plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.

Spider plots show deepening responses for onvansertib 30mg dose

Radiographic Response over Time* – as of November 26, 2024



* Radiographic response determined per RECIST 1.1 by blinded independent central review. Spider plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.

Swimmer plot shows most patients remain on trial

Radiographic Response over Time* – as of November 26, 2024



> On Treatment

Best Response

- # Confirmed Partial Response
- # Partial Response
- # Stable Disease
- # Progressive Disease

# indicates % change from baseline

Reason For Discontinuation

- To Pursue Surgery
- Adverse Event
- Progressive Disease

Chemotherapy Backbone

- IR FOLFIRI
- OX FOLFOX

* Radiographic response determined per RECIST 1.1 by blinded independent central review. Swimmer plot reflects interim data as of November 26, 2024 from an ongoing trial and unlocked database.

ORR is consistently higher for patients receiving onvansertib + SoC

Summary of Objective Response Rates by Cohort* – as of November 26, 2024

	CRDF-004 Evaluable Population (N = 30)				Historical Controls at End of Trial (Hecht, et al)**
		Onvansertib Arms			
	Control Arms	All	20mgs onv	30mgs onv	
FOLFIRI + bev	25% (1 of 4)	50% (6 of 12)	33% (2 of 6)	66% (4 of 6)	38%
FOLFOX + bev	40% (2 of 5)	66% (6 of 9)	75% (3 of 4)	60% (3 of 5)	44%
Total	33% (3 of 9)	57% (12 of 21)	50% (5 of 10)	64% (7 of 11)	

* Radiographic response determined per RECIST 1.1 by blinded independent central review. Interim data as of November 26, 2024 from an ongoing trial and unlocked database. Blue boxes indicate the 6 trial arms.

** Hecht et al., J Clin Oncol 2009 10 Feb; 27: 672-680

Demographics and baseline characteristics*

	Control Arms (SoC) N=9	SoC + Onvansertib 20mg N=10	SoC + Onvansertib 30mg N=11	Total N=30
Age (years)				
Median (range)	56.0 (32, 82)	47.0 (38, 69)	62.0 (39, 75)	55.5 (32, 82)
Gender, n (%)				
Male	6 (66.7)	4 (40.0)	6 (54.5)	16 (53.3)
Female	3 (33.3)	6 (60.0)	5 (45.5)	14 (46.7)
Race, n (%)				
White	8 (88.9)	9 (90.0)	11 (100)	28 (93.3)
Asian	1 (11.1)	0	0	1 (3.3)
Native Hawaiian or Other Pacific Islander	0	1 (10.0)	0	1 (3.3)
ECOG, n (%)				
0	4 (44.4)	6 (60.0)	8 (72.7)	18 (60.0)
1	5 (55.6)	4 (40.0)	3 (27.3)	12 (40.0)
Time to metastases, n (%)				
Metachronous	3 (33.3)	3 (30.0)	3 (27.3)	9 (30.0)
Synchronous	6 (66.7)	7 (70.0)	8 (72.7)	21 (70.0)
Side of Tumor, n (%)				
Bilateral	4 (44.4)	1 (10.0)	2 (18.2)	7 (23.3)
Left	2 (22.2)	4 (40.0)	3 (27.3)	9 (30.0)
Right	3 (33.3)	4 (40.0)	6 (54.5)	13 (43.3)
Liver metastasis at study entry, n (%)				
No	2 (22.2)	3 (30.0)	1 (9.1)	6 (20.0)
Yes	7 (77.8)	7 (70.0)	10 (90.9)	24 (80.0)
Liver only disease, n (%)				
No	7 (77.8)	10 (100)	8 (72.7)	25 (83.3)
Yes	2 (22.2)	0	3 (27.3)	5 (16.7)
Number of metastatic organs, n (%)				
Multiple	6 (66.7)	9 (90.0)	8 (72.7)	23 (76.7)
Single	3 (33.3)	1 (10.0)	3 (27.3)	7 (23.3)
Prior adjuvant or neo-adjuvant chemotherapy, n (%)				
No	7 (77.8)	7 (70.0)	10 (90.9)	24 (80.0)
Yes	2 (22.2)	3 (30.0)	1 (9.1)	6 (20.0)
Surgery on Primary tumor, n (%)				
No	4 (44.4)	5 (50.0)	7 (63.6)	16 (53.3)
Yes	5 (55.6)	5 (50.0)	4 (36.4)	14 (46.7)

* Demographics and baseline characteristics are as of November 26, 2024 from an ongoing trial and unlocked database. Side of tumor data for one patient is currently not available.

Treatment emergent adverse events (TEAE) data*

	FOLFIRI/Bev (N=4)		FOLFIRI/Bev/Onv 20mg (N=6)		FOLFIRI/Bev/Onv 30mg (N=6)		FOLFOX/Bev (N=5)		FOLFOX/Bev/Onv 20mg (N=4)		FOLFOX/Bev/Onv 30mg (N=5)		All Control Arms (N=9)		All Experimental Arms (N=21)	
N (% of total)	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3	All Grades	Gr ≥3
Any Adverse Events	4 (100.0)	2 (50.0)	6 (100.0)	4 (66.7)	6 (100.0)	5 (83.3)	5 (100.0)	3 (60.0)	4 (100.0)	3 (75.0)	5 (100.0)	3 (60.0)	9 (100.0)	5 (55.6)	21 (100.0)	15 (71.4)
Fatigue	2 (50.0)	0	3 (50.0)	0	3 (50.0)	0	4 (80.0)	1 (20.0)	3 (75.0)	0	3 (60.0)	0	6 (66.7)	1 (11.1)	12 (57.1)	0
Nausea	2 (50.0)	0	5 (83.3)	0	2 (33.3)	0	3 (60.0)	0	4 (100.0)	0	2 (40.0)	0	5 (55.6)	0	13 (61.9)	0
Neutrophil count decreased	4 (100.0)	1 (25.0)	2 (33.3)	1 (16.7)	2 (33.3)	1 (16.7)	2 (40.0)	2 (40.0)	3 (75.0)	1 (25.0)	1 (20.0)	0	6 (66.7)	3 (33.3)	8 (38.1)	3 (14.3)
Neutropenia	0 (0.0)	0	0	0	3 (50.0)	3 (50.0)	0	0	0	0	0	0	0	0	3 (14.3)	3 (14.3)
Thrombocytopenia	0 (0.0)	0	0	0	1 (16.7)	0	0	0	1 (25.0)	0	2 (40.0)	0	0	0	4 (19.0)	0
White blood cell count decreased	1 (25.0)	0	2 (33.3)	0	0	0	2 (40.0)	0	0	0	0	0	3 (33.3)	0	2 (9.5)	0
Lymphocyte count decreased	1 (25.0)	0	1 (16.7)	0	0	0	0	0	0	0	1 (20.0)	1 (20.0)	1 (11.1)	0	2 (9.5)	1 (4.8)
Diarrhoea	0 (0.0)	0	3 (50.0)	1 (16.7)	6 (100.0)	0	2 (40.0)	0	0	0	2 (40.0)	0	2 (22.2)	0	11 (52.4)	1 (4.8)
Abdominal pain	2 (50.0)	1 (25.0)	1 (16.7)	0	2 (33.3)	0	1 (20.0)	0	1 (25.0)	0	2 (40.0)	0	3 (33.3)	1 (11.1)	6 (28.6)	0
Vomiting	1 (25.0)	0	3 (50.0)	0	1 (16.7)	0	0	0	2 (50.0)	0	1 (20.0)	0	1 (11.1)	0	7 (33.3)	0
Alopecia	1 (25.0)	0	1 (16.7)	0	3 (50.0)	0	1 (20.0)	0	1 (25.0)	0	0	0	2 (22.2)	0	5 (23.8)	0
Anaemia	2 (50.0)	0	1 (16.7)	0	0	0	1 (20.0)	0	2 (50.0)	0	1 (20.0)	1 (20.0)	3 (33.3)	0	4 (19.0)	1 (4.8)
Peripheral sensory neuropathy	1 (25.0)	0	0	0	1 (16.7)	0	1 (20.0)	0	0	0	4 (80.0)	0	2 (22.2)	0	5 (23.8)	0
Constipation	0 (0.0)	0	1 (16.7)	0	3 (50.0)	0	0	0	1 (25.0)	0	1 (20.0)	0	0	0	6 (28.6)	0
Decreased appetite	0 (0.0)	0	1 (16.7)	0	2 (33.3)	0	0	0	2 (50.0)	0	1 (20.0)	0	0	0	6 (28.6)	0
Dizziness	0 (0.0)	0	1 (16.7)	0	2 (33.3)	0	1 (20.0)	0	0	0	2 (40.0)	0	1 (11.1)	0	5 (23.8)	0
Dysgeusia	0 (0.0)	0	0	0	2 (33.3)	0	1 (20.0)	0	2 (50.0)	0	1 (20.0)	0	1 (11.1)	0	5 (23.8)	0
Arthralgia	1 (25.0)	1 (25.0)	1 (16.7)	0	0	0	0	0	1 (25.0)	0	2 (40.0)	0	1 (11.1)	1 (11.1)	4 (19.0)	0
Dyspepsia	0 (0.0)	0	1 (16.7)	0	1 (16.7)	0	1 (20.0)	0	0	0	2 (40.0)	0	1 (11.1)	0	4 (19.0)	0
Headache	1 (25.0)	0	1 (16.7)	0	1 (16.7)	0	2 (40.0)	0	0	0	0	0	3 (33.3)	0	2 (9.5)	0
Insomnia	0 (0.0)	0	1 (16.7)	0	1 (16.7)	0	1 (20.0)	0	0	0	2 (40.0)	0	1 (11.1)	0	4 (19.0)	0
Weight decreased	0 (0.0)	0	1 (16.7)	0	2 (33.3)	0	0	0	1 (25.0)	0	1 (20.0)	0	0	0	5 (23.8)	0
Epistaxis	0 (0.0)	0	1 (16.7)	0	1 (16.7)	0	0	0	1 (25.0)	0	1 (20.0)	0	0	0	4 (19.0)	0
Hypertension	0 (0.0)	0	2 (33.3)	0	1 (16.7)	0	0	0	1 (25.0)	0	0	0	0	0	4 (19.0)	0
Hypokalaemia	0 (0.0)	0	0	0	1 (16.7)	0	1 (20.0)	0	0	0	2 (40.0)	0	1 (11.1)	0	3 (14.3)	0
Paraesthesia	0 (0.0)	0	0	0	0	0	1 (20.0)	0	0	0	3 (60.0)	0	1 (11.1)	0	3 (14.3)	0
Asthenia	0 (0.0)	0	0	0	2 (33.3)	1 (16.7)	1 (20.0)	0	0	0	0	0	1 (11.1)	0	2 (9.5)	1 (4.8)
Cough	1 (25.0)	0	2 (33.3)	0	0	0	0	0	0	0	0	0	1 (11.1)	0	2 (9.5)	0
Flushing	0 (0.0)	0	2 (33.3)	0	0	0	1 (20.0)	0	0	0	0	0	1 (11.1)	0	2 (9.5)	0
Haematochezia	1 (25.0)	0	0	0	2 (33.3)	0	0	0	0	0	0	0	1 (11.1)	0	2 (9.5)	0
Influenza like illness	1 (25.0)	0	2 (33.3)	0	0	0	0	0	0	0	0	0	1 (11.1)	0	2 (9.5)	0
Infusion related reaction	0 (0.0)	0	2 (33.3)	0	0	0	0	0	1 (25.0)	0	0	0	0	0	3 (14.3)	0
Neuropathy peripheral	0 (0.0)	0	0	0	0	0	2 (40.0)	0	1 (25.0)	0	0	0	2 (22.2)	0	1 (4.8)	0
Oedema peripheral	1 (25.0)	0	1 (16.7)	0	0	0	1 (20.0)	0	0	0	0	0	2 (22.2)	0	1 (4.8)	0
Proteinuria	1 (25.0)	0	0	0	0	0	0	0	1 (25.0)	0	1 (20.0)	0	1 (11.1)	0	2 (9.5)	0
Stomatitis	0 (0.0)	0	2 (33.3)	0	0	0	1 (20.0)	0	0	0	0	0	1 (11.1)	0	2 (9.5)	0

* Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. Columns show the absolute # of patients and (%) of the population

mCRC program positions onvansertib for accelerated and full-approval

mCRC clinical development program agreed with FDA at June 2023 Type C meeting

CRDF-004

1st line RAS-mutated mCRC trial
90 patients, randomized, 2 doses of onvansertib

Highlights of CRDF-004 exploratory trial

- Provide randomized clinical safety / efficacy data
- Confirm optimal dose in 1st line
- Pfizer Ignite provides clinical execution

CRDF-005

1st line RAS-mutated mCRC registrational trial
320 patients, randomized

Highlights of CRDF-005 registrational trial

- Registrational trial designed for accelerated and full approval, as agreed with FDA
- ORR endpoint: For accelerated approval
- PFS / OS trend endpoint: For full approval

AGENDA

1. 1st line RAS-mut mCRC trial data (CRDF-004)
2. **Commercial opportunity in 1st line mCRC**
3. The broader onvansertib opportunity

Factors driving the large TAM for onvansertib in 1st line RAS-mut mCRC

1. Large Patient Population: 48,000 new US cases per year (1st line RAS-mut mCRC)

Annual eligible US patients*



Onvansertib targets all RAS-mutated mCRC[1]



* Company estimates of first-line and second-line mCRC population with KRAS- and NRAS-mutated cancers.

1. Jones R et al. Br J Cancer. 2017 Mar 28;116(7):923-929

Factors driving the large TAM for onvansertib in 1st line RAS-mut mCRC

2. Significant Unmet Need: No new drugs approved in 20 years

Standard of Care for 1st / 2nd line RAS-mutated mCRC includes chemo + bevacizumab

Chemotherapy	FOLFOX FOLFIRI	(approved 1996) (approved 2002)
✚ / ▬		
Antiangiogenic	Bevacizumab (Avastin®)	(approved 2004)
Targeted therapy	None	

Factors driving the large TAM for onvansertib in 1st line RAS-mut mCRC

3. Straightforward adoption: No impediments to adding onvansertib to SoC

Onvansertib + SoC is well-tolerated

>380 patients have been dosed with onvansertib and it has been well-tolerated across multiple indications

Oral onvansertib is added to SoC



AGENDA

1. 1st line RAS-mut mCRC trial data (CRDF-004)
2. Commercial opportunity in 1st line mCRC
3. **The broader onvansertib opportunity**

Our pipeline opens many attractive opportunities for onvansertib

	Line of Therapy	Trial	IIT*	Ph2	Ph3	Combination with:
mCRC (RAS-mut)	1st line	CRDF-004 (w/Pfizer)		randomized		FOLFIRI/bev and FOLFOX/bev
	2nd line	Ph 1b/2		completed		FOLFIRI/bev
	2nd line	CRDF-003 (ONSEMBLE)		completed		FOLFIRI/bev
mPDAC	1st line	Ph 2	IIT	planned		NALIRIFOX
	2nd line	Ph 2		completed		Nal-IRI/leucovorin/ 5-FU
SCLC	2nd line	Ph 2	University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center			None (monotherapy)
TNBC	2nd line	Ph 2	Dana-Farber Cancer Institute			Paclitaxel

* For investigator-initiated trials (IITs) only, the investigator's institution is provided. The planned first-line mPDAC trial will be conducted by an investigator to be named.
mPDAC = metastatic pancreatic ductal adenocarcinoma; SCLC = small-cell lung cancer; TNBC = triple-negative breast cancer; bev= bevacizumab

Cardiff Oncology: Positioned to improve 1st line RAS-mut mCRC treatment

First-in-Class PLK1 inhibitor	Robust clinical data in 2L KRAS-mut mCRC	FDA / Pfizer	Clinical signal from CRDF-004 1L trial
• Onvansertib: first well-tolerated PLK1-selective inhibitor • PLK1 inhibition disrupts tumor growth several ways	Ph 1b/2 bev naïve data • 73% response rate • 15 month progression free survival	• FDA-agreed path to 1st line RAS-mut mCRC accelerated approval • Pfizer is equity investor and has seat on SAB • Pfizer provides clinical execution of 1st line trial	• 64% response rate for 30 mg onvansertib + SoC patients with deeper tumor regression • 33% response rate for SoC alone patients

We expect additional clinical data from our 1st line RAS-mutated mCRC trial in H1 2025

APPENDIX

FOLFIRI/Bev Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	4 (100.0)	2 (50.0)	2 (50.0)	0 (0.0)	4 (100.0)
Fatigue	1 (25.0)	1 (25.0)	0 (0.0)	0 (0.0)	2 (50.0)
Nausea	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)
Neutrophil count decreased	1 (25.0)	2 (50.0)	1 (25.0)	0 (0.0)	4 (100.0)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White blood cell count decreased	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Lymphocyte count decreased	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Diarrhoea	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal pain	1 (25.0)	0 (0.0)	1 (25.0)	0 (0.0)	2 (50.0)
Vomiting	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Alopecia	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Anaemia	1 (25.0)	1 (25.0)	0 (0.0)	0 (0.0)	2 (50.0)
Peripheral sensory neuropathy	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Constipation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dysgeusia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Arthralgia	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)	1 (25.0)
Dyspepsia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Insomnia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Weight decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypokalaemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Paraesthesia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cough	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Flushing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Haematochezia	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Influenza like illness	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Infusion related reaction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neuropathy peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oedema peripheral	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Proteinuria	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Stomatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Control arm

FOLFIRI/Bev (N=4)

- Patients received FOLFIRI+Bev

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population

FOLFIRI/Bev/Onvansertib 20mg Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	6 (100.0)	6 (100.0)	4 (66.7)	0 (0.0)	6 (100.0)
Fatigue	2 (33.3)	1 (16.7)	0 (0.0)	0 (0.0)	3 (50.0)
Nausea	2 (33.3)	3 (50.0)	0 (0.0)	0 (0.0)	5 (83.3)
Neutrophil count decreased	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	2 (33.3)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White blood cell count decreased	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)
Lymphocyte count decreased	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)
Diarrhoea	1 (16.7)	1 (16.7)	1 (16.7)	0 (0.0)	3 (50.0)
Abdominal pain	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Vomiting	1 (16.7)	2 (33.3)	0 (0.0)	0 (0.0)	3 (50.0)
Alopecia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Anaemia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Peripheral sensory neuropathy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Decreased appetite	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)
Dizziness	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Dysgeusia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Arthralgia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Dyspepsia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Headache	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Insomnia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Weight decreased	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Epistaxis	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Hypertension	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (33.3)
Hypokalaemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Paraesthesia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cough	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)
Flushing	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)
Haematochezia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Influenza like illness	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)
Infusion related reaction	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (33.3)
Neuropathy peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oedema peripheral	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Proteinuria	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stomatitis	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)

Experimental arm

FOLFIRI/Bev/Onv 20mg (N=6)

- Patients received FOLFIRI + Bev +20 mg dose of onvansertib

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population

FOLFIRI/Bev/Onvansertib 30mg Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	6 (100.0)	5 (83.3)	5 (83.3)	2 (33.3)	6 (100.0)
Fatigue	3 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (50.0)
Nausea	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)
Neutrophil count decreased	1 (16.7)	0 (0.0)	1 (16.7)	0 (0.0)	2 (33.3)
Neutropenia	0 (0.0)	0 (0.0)	1 (16.7)	2 (33.3)	3 (50.0)
Thrombocytopenia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
White blood cell count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lymphocyte count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhoea	5 (83.3)	1 (16.7)	0 (0.0)	0 (0.0)	6 (100.0)
Abdominal pain	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)
Vomiting	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Alopecia	3 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (50.0)
Anaemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Peripheral sensory neuropathy	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Constipation	1 (16.7)	2 (33.3)	0 (0.0)	0 (0.0)	3 (50.0)
Decreased appetite	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (33.3)
Dizziness	0 (0.0)	2 (33.3)	0 (0.0)	0 (0.0)	2 (33.3)
Dysgeusia	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)
Arthralgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dyspepsia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Headache	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Insomnia	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Weight decreased	1 (16.7)	1 (16.7)	0 (0.0)	0 (0.0)	2 (33.3)
Epistaxis	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
Hypertension	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)
Hypokalaemia	0 (0.0)	1 (16.7)	0 (0.0)	0 (0.0)	1 (16.7)
Paraesthesia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	0 (0.0)	1 (16.7)	1 (16.7)	0 (0.0)	2 (33.3)
Cough	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flushing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Haematochezia	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)
Influenza like illness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Infusion related reaction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neuropathy peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oedema peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stomatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Experimental arm

FOLFIRI/Bev/Onv 30mg (N=6)

- Patients received FOLFIRI + Bev + 30 mg dose of onvansertib
- Grade 4 neutropenia in both patients resolved in 9 and 16 days. Treatment was delayed by 7 and 15 days, respectively until the AE resolved.
- Both patients are still on study treatment.

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population

FOLFOX/Bev Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	4 (80.0)	5 (100.0)	2 (40.0)	1 (20.0)	5 (100.0)
Fatigue	3 (60.0)	0 (0.0)	1 (20.0)	0 (0.0)	4 (80.0)
Nausea	1 (20.0)	2 (40.0)	0 (0.0)	0 (0.0)	3 (60.0)
Neutrophil count decreased	0 (0.0)	0 (0.0)	1 (20.0)	1 (20.0)	2 (40.0)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
White blood cell count decreased	0 (0.0)	2 (40.0)	0 (0.0)	0 (0.0)	2 (40.0)
Lymphocyte count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhoea	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	2 (40.0)
Abdominal pain	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Vomiting	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Alopecia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Anaemia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Peripheral sensory neuropathy	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Constipation	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased appetite	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dizziness	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Dysgeusia	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	1 (20.0)
Arthralgia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dyspepsia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Headache	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)
Insomnia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Weight decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Epistaxis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypertension	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypokalaemia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Paraesthesia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Asthenia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Cough	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flushing	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	1 (20.0)
Haematochezia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Influenza like illness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Infusion related reaction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neuropathy peripheral	0 (0.0)	2 (40.0)	0 (0.0)	0 (0.0)	2 (40.0)
Oedema peripheral	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Proteinuria	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stomatitis	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)

Control arm

FOLFOX/Bev (N=5)

- Patients received FOLFOX+ Bev
- Grade 4 neutropenia resolved in 8 days. Treatment was delayed for 8 days until the AE resolved.
- Patient is still on study treatment.

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population

FOLFOX/Bev/Onvansertib 20mg Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	4 (100.0)	4 (100.0)	3 (75.0)	0 (0.0)	4 (100.0)
Fatigue	2 (50.0)	1 (25.0)	0 (0.0)	0 (0.0)	3 (75.0)
Nausea	2 (50.0)	2 (50.0)	0 (0.0)	0 (0.0)	4 (100.0)
Neutrophil count decreased	2 (50.0)	0 (0.0)	1 (25.0)	0 (0.0)	3 (75.0)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
White blood cell count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lymphocyte count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhoea	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Abdominal pain	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Vomiting	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)
Alopecia	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Anaemia	0 (0.0)	2 (50.0)	0 (0.0)	0 (0.0)	2 (50.0)
Peripheral sensory neuropathy	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Constipation	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Decreased appetite	1 (25.0)	1 (25.0)	0 (0.0)	0 (0.0)	2 (50.0)
Dizziness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Dysgeusia	2 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)
Arthralgia	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Dyspepsia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Headache	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Insomnia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Weight decreased	1 (25.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (25.0)
Epistaxis	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Hypertension	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Hypokalaemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Paraesthesia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Asthenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cough	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flushing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Haematochezia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Influenza like illness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Infusion related reaction	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Neuropathy peripheral	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Oedema peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)
Stomatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Experimental arm

FOLFOX/Bev/Onv 20mg (N=4)

- Patients received FOLFOX+ Bev +20 mg dose of onvansertib

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population

FOLFOX/Bev/Onvansertib 30mg Treatment Emergent Adverse Effects (TEAEs)

N (% of total)	Grade 1	Grade 2	Grade 3	Grade 4	Total
Any Adverse Events	5 (100.0)	4 (80.0)	3 (60.0)	0 (0.0)	5 (100.0)
Fatigue	3 (60.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (60.0)
Nausea	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	2 (40.0)
Neutrophil count decreased	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Neutropenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Thrombocytopenia	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	2 (40.0)
White blood cell count decreased	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Lymphocyte count decreased	0 (0.0)	0 (0.0)	1 (20.0)	0 (0.0)	1 (20.0)
Diarrhoea	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	2 (40.0)
Abdominal pain	0 (0.0)	2 (40.0)	0 (0.0)	0 (0.0)	2 (40.0)
Vomiting	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	1 (20.0)
Alopecia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Anaemia	0 (0.0)	0 (0.0)	1 (20.0)	0 (0.0)	1 (20.0)
Peripheral sensory neuropathy	3 (60.0)	1 (20.0)	0 (0.0)	0 (0.0)	4 (80.0)
Constipation	0 (0.0)	1 (20.0)	0 (0.0)	0 (0.0)	1 (20.0)
Decreased appetite	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Dizziness	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)
Dysgeusia	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Arthralgia	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)
Dyspepsia	1 (20.0)	1 (20.0)	0 (0.0)	0 (0.0)	2 (40.0)
Headache	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Insomnia	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)
Weight decreased	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Epistaxis	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Hypertension	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Hypokalaemia	2 (40.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (40.0)
Paraesthesia	3 (60.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (60.0)
Asthenia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Cough	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Flushing	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Haematochezia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Influenza like illness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Infusion related reaction	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Neuropathy peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Oedema peripheral	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Proteinuria	1 (20.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (20.0)
Stomatitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Experimental arm

FOLFOX/Bev/Onv 30mg (N=5)

- Patients received FOLFOX+ Bev + 30 mg dose of onvansertib

Data consists of all adverse events entered into the EDC as of Nov 26, 2024, from an ongoing trial and unlocked EDC database. N: number of patients; events shown occurred in ≥10% of total patients; numbers indicate number of patients experiencing the event, (regardless of causality); each patient is only counted once and only for the highest grade of a given event. TEAEs: Treatment Emergent Adverse Events; Columns show the absolute # of patients and (%) of the population